methyl (2'-chloro-[1,1'-biphenyl])-3-carboxylate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl (2'-chloro-[1,1'-biphenyl])-3-carboxylate
• 英文别名: Methyl 2'-chloro[1,1'-biphenyl]-3-carboxylate；methyl 3-(2-chlorophenyl)benzoate
• 化学式: C₁₄H₁₁ClO₂
• 分子量: 246.693
• InChiKey: ZRBYBHMVOOJEDE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  methyl (2'-chloro-[1,1'-biphenyl])-3-carboxylate 在 4-二甲氨基吡啶 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 40.0h， 生成 (2S,3S)-methyl 2-((2'-chloro-[1,1'-biphenyl]-3-yl)formamido)-3-methylpentanoate
  参考文献：
  名称：

  Synthesis and activity of isoleucine sulfonamide derivatives as novel botulinum neurotoxin serotype A light chain inhibitors

  摘要：

  The botulinum neurotoxin (BoNT) is the most lethal protein known to man causing the deadly disease botulinum. The neurotoxin, composed of a heavy (HC) and light (LC) chain, work in concert to cause muscle paralysis. A therapeutic strategy to treat individuals infected with the neurotoxin is inhibiting the catalytic activity of the BoNT LC. We report the synthesis, inhibition study and computational docking analysis of novel small molecule BoNT/A LC inhibitors. A structure activity relationship study resulted in the discovery of D-isoleucine functionalized with a hydroxamic acid on the C-terminal and a biphenyl with chlorine at C- 2 connected by a sulfonamide linker at the N-terminus. This compound has a measured IC50 of 0.587 mu M for the BoNT/A LC. Computational docking analysis indicates the sulfonamide linker adopts a geometry that is advantageous for binding to the BoNT LC active site. In addition, Arg363 is predicted to be involved in key binding interactions with the scaffold in this study.

  DOI：

  10.1016/j.bmc.2020.115659
• 作为产物：
  描述：

  3-溴苯甲酸甲酯 、 2-氯苯基硼酸 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 乙醇 、 水 为溶剂， 反应 0.17h， 以93%的产率得到methyl (2'-chloro-[1,1'-biphenyl])-3-carboxylate
  参考文献：
  名称：

  Synthesis and activity of isoleucine sulfonamide derivatives as novel botulinum neurotoxin serotype A light chain inhibitors

  摘要：

  The botulinum neurotoxin (BoNT) is the most lethal protein known to man causing the deadly disease botulinum. The neurotoxin, composed of a heavy (HC) and light (LC) chain, work in concert to cause muscle paralysis. A therapeutic strategy to treat individuals infected with the neurotoxin is inhibiting the catalytic activity of the BoNT LC. We report the synthesis, inhibition study and computational docking analysis of novel small molecule BoNT/A LC inhibitors. A structure activity relationship study resulted in the discovery of D-isoleucine functionalized with a hydroxamic acid on the C-terminal and a biphenyl with chlorine at C- 2 connected by a sulfonamide linker at the N-terminus. This compound has a measured IC50 of 0.587 mu M for the BoNT/A LC. Computational docking analysis indicates the sulfonamide linker adopts a geometry that is advantageous for binding to the BoNT LC active site. In addition, Arg363 is predicted to be involved in key binding interactions with the scaffold in this study.

  DOI：

  10.1016/j.bmc.2020.115659

文献信息

• [EN] GUANIDINE DERIVATIVES AS INHIBITORS OF Na/H EXCHANGE IN CELLS<br/>[FR] DERIVES DE GUANIDINE, UTILISES COMME INHIBITEURS DE L'ECHANGE DE Na/H DANS LES CELLULES
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：WO1994026709A1

  公开（公告）日：1994-11-24

  (EN) Guanidine derivatives of formula (I), wherein Y is N or C-R1 (in which R1 is hydrogen, lower alkyl, hydroxy, protected hydroxy, etc.), R2 is hydrogen, aryl which may have one suitable substituent, aryloxy, etc., R3 is hydrogen, lower alkoxy, hydroxy, protected hydroxy, etc., Z is N or C-R4 (in which R4 is hydrogen, carboxy, protected carboxy, nitro, halogen, hydroxy(lower)alkyl, etc.), and W is N or C-R12 (in which R12 is hydrogen, lower alkoxy, nitro, hydroxy or protected hydroxy), and pharmaceutically acceptable salts thereof which are useful as a medicament.(FR) L'invention se rapporte à des dérivés de guanidine, représentés par la formule (I), où Y représente N ou C-R1 (où R1 représente hydrogène, alkyle inférieur, hydroxy, hydroxy protégé, etc.), R2 représente hydrogène, aryle qui peut comporter un substituant approprié, aryloxy, etc., R3 représente hydrogène, alcoxy inférieur, hydroxy, hydroxy protégé, etc., Z représente N ou C-R4 (où R4 représente hydrogène, carboxy, carboxy protégé, nitro, halogène, hydroxy alkyle (inférieur), etc.), et W représente N ou C-R12 (où R12 représente hydrogène, alcoxy inférieur, nitro, hydroxy ou hydroxy protégé), ainsi qu'à des sels pharmaceutiquement acceptables de ces dérivés, utiles comme médicaments.

  (中) 公式(I)中的guanidine衍生物，其中Y是N或C-R1（其中R1是氢，低烷基，羟基，保护羟基等），R2是氢，芳基（可能有一个适当的取代基），芳氧基等，R3是氢，低烷氧基，羟基，保护羟基等，Z是N或C-R4（其中R4是氢，羧基，保护羧基，硝基，卤素，羟基（低）烷基等），W是N或C-R12（其中R12是氢，低烷氧基，硝基，羟基或保护羟基），以及其药学上可接受的盐，可用作药物。
• Lactams as EP4 prostanoid receptor subtype selective agonists. Part 1: 2-Pyrrolidinones-stereochemical and lower side-chain optimization
  作者：Todd R. Elworthy、Denis J. Kertesz、Woongki Kim、Michael G. Roepel、Lina Quattrocchio-Setti、David B. Smith、Jahari Laurant Tracy、Audrey Chow、Fujun Li、Emma R. Brill、Leang K. Lach、Daren McGee、Diana S. Yang、San-San Chiou

  DOI：10.1016/j.bmcl.2004.01.063

  日期：2004.4

  A series of 7-[(5R)-substituted 2-oxo-1-pyrrolidinyl]-heptanoic acids were prepared, their isomeric purity determined, and pharmacologically evaluated. Lactams with affinity for the EP4 receptor displayed agonist behavior. The lower side-chain of the lactam template could be substituted to afford ligands (e.g., 17, 24, 30, 31, and 33) of high potency and greater than 1000-fold affinity for EP4 versus the other EP prostanoid receptors. (C) 2004 Elsevier Ltd. All rights reserved.
• GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0699185A1

  公开（公告）日：1996-03-06
• US5824691A
  申请人：——

  公开号：US5824691A

  公开（公告）日：1998-10-20
• Synthesis and activity of isoleucine sulfonamide derivatives as novel botulinum neurotoxin serotype A light chain inhibitors
  作者：Jordan C. Thompson、Wendy T. Dao、Alex Ku、Sandra L. Rodriguez-Beltran、Martin Amezcua、Alejandra Y. Palomino、Thanh Lien、Nicholas T. Salzameda

  DOI：10.1016/j.bmc.2020.115659

  日期：2020.9

  The botulinum neurotoxin (BoNT) is the most lethal protein known to man causing the deadly disease botulinum. The neurotoxin, composed of a heavy (HC) and light (LC) chain, work in concert to cause muscle paralysis. A therapeutic strategy to treat individuals infected with the neurotoxin is inhibiting the catalytic activity of the BoNT LC. We report the synthesis, inhibition study and computational docking analysis of novel small molecule BoNT/A LC inhibitors. A structure activity relationship study resulted in the discovery of D-isoleucine functionalized with a hydroxamic acid on the C-terminal and a biphenyl with chlorine at C- 2 connected by a sulfonamide linker at the N-terminus. This compound has a measured IC50 of 0.587 mu M for the BoNT/A LC. Computational docking analysis indicates the sulfonamide linker adopts a geometry that is advantageous for binding to the BoNT LC active site. In addition, Arg363 is predicted to be involved in key binding interactions with the scaffold in this study.